Known potential treatment strategies for COL4As-related nephropathy include angiotensin-converting enzyme inhibitors, which may delay disease progression [26], the Nrf2 activator bardoxolone [27], and gene therapy for COL4A5 mutations [28]. The gene discussed is ACE; the disease is kidney disorder.